CoChat

Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans

Ayyar, Vivaswath S., Song, Dawei, Zheng, Songmao, Carpenter, Thomas, Heald, Donald L. · 2021 · The Journal of Pharmacology and Experimental Therapeutics
Cited by 49

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Conjugation of small interfering RNA (siRNA) to tris N-acetylgalactosamine [(GalNAc)3] can enable highly selective, potent, and durable knockdown of targeted proteins in the liver. However, potential knowledge gaps between in vitro experiments, preclinical species, and clinical scenarios remain. A minimal physiologically based pharmacokinetic-pharmacodynamic model for GalNAc-conjugated siRNA (GalNAc-siRNA) was developed using published data for fitusiran (ALN-AT3), an investigational compound targeting liver antithrombin (AT), to delineate putative determinants governing the whole-body–to-cellular pharmacokinetic (PK) and pharmacodynamic (PD) properties of GalNAc-siRNA and facilitate preclinical-to-clinical translation. The model mathematically linked relevant mechanisms: 1) hepatic biodistribution, 2) tris-GalNAc binding to asialoglycoprotein receptors (ASGPRs) on hepatocytes, 3) ASGPR endocytosis and recycling, 4) endosomal transport and escape of siRNA, 5) cytoplasmic RNA-induced silencing complex (RISC) loading, 6) degradation of target mRNA by bound RISC, and 7) knockdown of protein. Physiologic values for 36 out of 48 model parameters were obtained from the literature. Kinetic parameters governing (GalNAc)3-ASGPR binding and internalization were derived from published studies of uptake in hepatocytes. The proposed model well characterized reported pharmacokinetics, RISC dynamics, and knockdown of AT mRNA and protein by ALN-AT3 in mice. The model bridged multiple PK-PD data sets in preclinical species (mice, rat, monkey) and successfully captured reported plasma pharmacokinetics and AT knockdown in a phase I ascending-dose study. Estimates of in vivo potency were similar (∼2-fold) across species. Subcutaneous absorption and serum AT degradation rate constants scaled across species by body weight with allometric exponents of −0.29 and −0.22. The proposed mechanistic modeling framework characterizes the unique PK-PD properties of GalNAc-siRNA. SIGNIFICANCE STATEMENT Tris N-acetylgalactosamine (GalNAc)3–conjugated small interfering RNA (siRNA) therapeutics enable liver-targeted gene therapy and precision medicine. Using a translational and systems-based minimal physiologically based pharmacokinetic-pharmacodynamic (mPBPK-PD) modeling approach, putative determinants influencing GalNAc-conjugated siRNA (GalNAc-siRNA) functionality in three preclinical species and humans were investigated. The developed model successfully integrated and characterized relevant published in vitro–derived biomeasures, mechanistic PK-PD profiles in animals, and observed clinical PK-PD responses for an investigational GalNAc-siRNA (fitusiran). This modeling effort delineates the disposition and liver-targeted pharmacodynamics of GalNAc-siRNA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1124/jpet.121.000805

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • A methodology for performing global uncertainty and sensitivity analysis in systems biology

    Marino, S., Hogue, I. B., Ray, C. J., & Kirschner, D. E. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.04.011 · Cited by 2,999 · cited 11×

    “Introduction: 701 Discussion: 1824 (limit exceeded to address reviewers’ comments) List of non-standard abbreviations: ASGPR, asialoglycoprotein receptor; AT, antithrombin; FIH, firstin-human; GalNAc, N-acetylgalactosamine; GSA, global sensitivity analysis; KP, tissue:plasma partition coefficient; mPBPK, minimal physi…”
    BackgroundInfluential
  • Delivery materials for siRNA therapeutics

    Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800 · cited 3×

    “To derive the association rate constant (kon) for (GalNAc)3 with ASGPR (Table 2), a reported value of 2.48 nM for the equilibrium dissociation constant (KD) of this interaction was utilized (Kanasty et al., 2013).”
    BackgroundMethodInfluential
  • Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape

    Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681

  • Therapeutic siRNA: state of the art

    Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586 · cited 4×

    “…siRNA compounds, the clinical pipeline for GalNAc-siRNA therapy has increased substantially, with over a dozen late-stage trials to treat diverse liver-related diseases now underway (Khvorova and Watts, 2017; Springer and Dowdy, 2018; Setten et al., 2019; Debacker et al., 2020; Hu et al., 2020).”
    BackgroundInfluential
  • The current state and future directions of RNAi-based therapeutics

    Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443 · cited 2×

    “…siRNA compounds, the clinical pipeline for GalNAc-siRNA therapy has increased substantially, with over a dozen late-stage trials to treat diverse liver-related diseases now underway (Khvorova and Watts, 2017; Springer and Dowdy, 2018; Setten et al., 2019; Debacker et al., 2020; Hu et al., 2020).”
    Background
  • The chemical evolution of oligonucleotide therapies of clinical utility

    Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216 · cited 2×

    “…siRNA compounds, the clinical pipeline for GalNAc-siRNA therapy has increased substantially, with over a dozen late-stage trials to treat diverse liver-related diseases now underway (Khvorova and Watts, 2017; Springer and Dowdy, 2018; Setten et al., 2019; Debacker et al., 2020; Hu et al., 2020).”
    Background
  • Multivalent N -Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing

    Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141 · cited 1×

    “…to one strand of the siRNA duplex to lower immunogenicity, lipid nanoparticle formulations, and the development of tris N-acetylgalactosamine (GalNAc)3-conjugated siRNA (GalNAc-siRNA hereafter) (Layzer et al., 2004; Nair et al., 2014; Khvorova and Watts, 2017; Springer and Dowdy, 2018).”
    Background
  • Overcoming cellular barriers for RNA therapeutics

    Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139 · cited 5×

    “These compounds offer the ability to target previously undruggable human and viral genomes to selectively knock down diseasecausing proteins (Dowdy, 2017).”
    BackgroundInfluential
  • GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics

    Springer, A. D., & Dowdy, S. F. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0736 · Cited by 711 · cited 3×

    “…siRNA compounds, the clinical pipeline for GalNAc-siRNA therapy has increased substantially, with over a dozen late-stage trials to treat diverse liver-related diseases now underway (Khvorova and Watts, 2017; Springer and Dowdy, 2018; Setten et al., 2019; Debacker et al., 2020; Hu et al., 2020).”
    Background
  • Hepatocytes: a key cell type for innate immunity

    Zhou, Z., Xu, M.-J., & Gao, B. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.97 · Cited by 472 · cited 1×

    “Upon binding to ASGPR, GalNAc-siRNA was assumed to distribute within the total volume of hepatocytes, which comprise 80% of the cellular volume of liver (Zhou et al., 2016).”
    Background

Show all 12 references

Cited by

See all 49

Metadata

Authors
Ayyar, V. S., Song, D., Zheng, S., Carpenter, T., & Heald, D. L.
Venue
The Journal of Pharmacology and Experimental Therapeutics
Publisher
Elsevier BV
Published
2021-11
Volume
379
Issue
2
Pages
134-146
ISSN
0022-3565 (ISSN-L)
OpenAlex
W3195372454
Cited by
49
References
12
FWCI
1.95
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans. https://app.cochat.ai/papers/10.1124/jpet.121.000805
The paper
Ayyar, V. S., Song, D., Zheng, S., Carpenter, T., & Heald, D. L. (2021). Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.121.000805

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.